This site is intended for health professionals only
Saturday 19 January 2019
Share |

Latest News

New treatment for prostate cancer receives European licence

Thursday 17th January 2019
Janssen has announced that the European Commission (EC) has licensed Erleada (apalutamide), for the treatment of men with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.
Prostate cancer is the most common cancer in men in the UK,1 resulting in over 47,000 diagnoses each year, or 129 each day.2
The licence is based on...